| Literature DB >> 28361664 |
Francesca Mulas1, Amy Li1, David H Sherr2, Stefano Monti3.
Abstract
BACKGROUND: Methods for inference and comparison of biological networks are emerging as powerful tools for the identification of groups of tightly connected genes whose activity may be altered during disease progression or due to chemical perturbations. Connectivity-based comparisons help identify aggregate changes that would be difficult to detect with differential analysis methods comparing individual genes.Entities:
Keywords: Chemical perturbations; Comparative analysis; Compounds similarity; Correlation networks; Gene expression; Toxicogenomics
Mesh:
Substances:
Year: 2017 PMID: 28361664 PMCID: PMC5374700 DOI: 10.1186/s12859-017-1536-9
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Fig. 1Analysis workflow. DrugMatrix liver samples are used to infer chemical-specific Compound Networks (a) and a Control Network (b). Similarity in terms of network structure is evaluated to identify groups of compounds, whose samples are pooled to infer Aggregate Compound Networks (c-e). Modules of tightly connected genes both in the Control network and in Compound Aggregate networks are identified and compared across conditions in terms of Module Differential Connectivity (MDC) (f). Modules with a change in connectivity that is highly specific to each compound group are investigated through pathway enrichment analysis (g-h)
Fig. 2Compounds aggregation. Similarity of 62 chemical compounds based on adjusted Rand Index (aRI). a. Heatmap of aRI and grouping of compounds with similar networks structure. b. Zoom-in on the compounds grouping
Compound groups. Main functions retrieved through the STITCH database
| Group ID - Main Function | Compounds | Functions |
|---|---|---|
| G1 - Solvents | carbon tetrach | cleaning agent |
| chloroform | solvent | |
| dimethylformamide | solvent | |
| allyl alcohol | alcohol | |
| 1-naphthyl isothiocyanate | preservative | |
| lipo-polysaccharide | endotoxin | |
| G2 - Antifungals | clotrimazole | antifungal |
| fluconazole | antifungal | |
| miconazole | antifungal | |
| mifepristone | steroid | |
| G3 - Statins | cerivastatin | statin |
| fluvastatin | statin | |
| lovastatin | statin | |
| simvastatin | statin | |
| G4 - Estrogens | diethylstilbestrol | estrogen |
| beta-estradiol | estrogen | |
| ethinylestradiol | estrogen | |
| G5 - Fibrates | aspirin | anti-inflammatory |
| fenofibrate | fibrate | |
| gemfibrozil | fibrate | |
| bezafibrate | fibrate | |
| G6 - Steroids | bithionol | photosensitizer |
| norethisterone | progestogens | |
| progesterone | progestogens | |
| retinoic acid | progestogens regulator | |
| G7 - n.c | atorvastatin | statin |
| econazole | antifungal | |
| raloxifene | estrogen | |
| phenothiazine | antipsychotic | |
| G8 - Anti-Cancer | catechol | benzenediols |
| azathioprine | cancer drug | |
| ifosfamide | cancer drug | |
| leflunomide | antirheumatic | |
| letrozole | cancer drug | |
| phenobarbital | anticonvulsant | |
| zomepirac | antipyretic | |
| diethylnitrosamine | tumorigenic | |
| G9 - Chemotherapeutics | doxorubicin | chemotherapeutic |
| procarbazine | chemotherapeutic | |
| promethazine | neuroleptic | |
| mitomycin C | chemotherapeutic | |
| gefitinib | cancer drug | |
| erlotinib | cancer drug | |
| tandutinib | antineoplastic | |
| balsalazide | anti-inflammatory | |
| G10 - Alkylating, Cancer | altretamine. | alkylating |
| lomustine | cancer drug | |
| imatinib | cancer drug | |
| G11 - n.c. | chlorambucil | cancer drug |
| enoxacin | antibacterial | |
| fluphenazine | antipsychotic | |
| G12 - Anti-Inflamm/ Fungal | dexamethasone | anti-inflammatory |
| itraconazole | anti-fungal | |
| ketoconazole | anti-fungal | |
| meloxicam | anti-inflammatory | |
| sulindac | anti-inflammatory | |
| 6-thioguanine | anti-inflammatory/cancer | |
| G13 - Antiseptics, Estrogens | clonazepam | anxiolytic |
| cyproterone acetate | estrogenic | |
| estradiol benzoate | estrogenic | |
| safrole | antiseptic | |
| methyl salicylate | antiseptic |
Groups’ internal similarity by multiple criteria
| Group | Function | Significance of interacting proteins | Significance of common side effects |
|---|---|---|---|
| G1 | Solvents | 6.61E-33 * | NA |
| G2 | Antifungals | 4.45E-19 * | 8.47E-11 |
| G3 | Statins | 1.69E-33 * | 1.29E-145 * |
| G4 | Estrogens | NA | NA |
| G5 | Fibrates | 1.02E-56 * | 6.60E-20 |
| G6 | Steroids | 1.56E-06 * | NA |
| G7 | n.c. (estrogens, antifungals) | 0.0002 | 1.77E-05 |
| G8 | Anti-Cancer | 1.69E-06 * | 7.91E-16 |
| G9 | Chemoterapeutics | 9.79E-05 | 1.78E-32 * |
| G10 | Alkylating, Cancer | 0.0001 | 2.79E-07 |
| G11 | n.c (anti-cancer, estrogens) | 0.0012 | 4.80E-15 |
| G12 | Anti-Inflamm/ Fungal | 1.28E-18 * | 2.91E-18 |
| G13 | Antiseptics, Estrogens | 0.0004 | NA |
NA = no annotations were found in CTD or in SIDER. * = lower p-value cannot be obtained by chance (permutations)
Fig. 3Gain and loss of connectivity of Control modules. Differential connectivity of 60 Control modules (rows) induced by 13 groups of compounds (columns). The heatmap is color-coded according to the MDC values, with blue and red indicating a loss and a gain of connectivity, respectively
Fig. 4Enrichment of specific Control modules. Bipartite graph representing associations between compound groups and enriched Hallmarks gene set corresponding to specifically altered modules extracted from the Control Network
Fig. 5Enrichment of specific Compounds-related modules. Bipartite graph representing associations between compound groups and enriched Hallmark gene sets corresponding to specifically altered modules extracted from each Aggregate Compound Network